Immusoft Corporation, a cell therapy company dedicated to improving the lives of patients with rare diseases, today announced that it will feature oral and poster presentations at the upcoming ...
NEWARK, Del, Jan. 02, 2025 (GLOBE NEWSWIRE) -- The global mucopolysaccharidosis treatment market, valued at USD 2,669.1 million in 2024, is estimated to grow at a compound annual growth rate (CAGR ...
Discover Sanfilippo Syndrome a rare genetic disorder affecting childrens development Learn about its symptoms treatment ...
NEWARK, Del, Jan. 02, 2025 (GLOBE NEWSWIRE) -- The global mucopolysaccharidosis treatment market, valued at USD 2,669.1 million in 2024, is estimated to grow at a compound annual growth rate (CAGR) of ...
Regenxbio (RGNX) and Nippon Shinyaku announced a strategic partnership for the development and commercialization of RGX-121 for the treatment ...
REGENXBIO Inc. (RGNX) and Nippon Shinyaku announced a strategic partnership for the development and commercialization of RGX-121 for ...
REGENXBIO's partnership with Nippon Shinyaku provides $110M upfront, ensuring a cash runway for gene therapy programs in MPS ...
It is a recessive X-linked disease, which means mothers have a 50 per cent chance of passing it to their sons. It is rare and ...
Equities researchers at Cantor Fitzgerald issued their FY2025 earnings per share estimates for Ultragenyx Pharmaceutical in a ...
Shares of Regenxbio Inc . (NASDAQ: RGNX) surged 18.4% in pre-open trading Tuesday following the announcement of a strategic partnership with Nippon Shinyaku Co., Ltd. for the development and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback